International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2010, Volume 76, Issue 3, pp. S123 - S129
The available dose/volume/outcome data for rectal injury were reviewed. The volume of rectum receiving ≥60Gy is consistently associated with the risk of Grade...
Radiology | Hematology, Oncology and Palliative Medicine | Radiation injury | Rectum | NTCP | MULTICENTER | ONCOLOGY-GROUP | LOCALIZED PROSTATE-CANCER | TISSUE COMPLICATION PROBABILITY | TRIAL | IRRADIATION | LATE TOXICITY | ONCOLOGY | CONFORMAL RADIOTHERAPY | HISTOGRAMS | QUALITY-OF-LIFE | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Radiography | Radiotherapy Dosage | Rectum - diagnostic imaging | Gastrointestinal Hemorrhage - etiology | Models, Biological | Humans | Radiotherapy, Conformal - adverse effects | Risk | Rectum - radiation effects | Models, Statistical | Radiation Injuries - complications | Forecasting | Medical colleges | Analysis | Oncology, Experimental | Radiation | Research | Prostate cancer | Cancer | Index Medicus | GASTROINTESTINAL TRACT | LARGE INTESTINE | BEAMS | DIGESTIVE SYSTEM | RADIATION EFFECTS | PROTON BEAMS | MALE GENITALS | RADIATION DOSES | THREE-DIMENSIONAL CALCULATIONS | MEDICINE | PARTICLE BEAMS | RADIATION DOSE DISTRIBUTIONS | HEALTH HAZARDS | THERAPY | GLANDS | BIOLOGICAL EFFECTS | RADIOLOGY AND NUCLEAR MEDICINE | BIOLOGICAL RADIATION EFFECTS | NUCLEON BEAMS | RADIOTHERAPY | RADIOLOGY | PROSTATE | INJURIES | NEOPLASMS | RECTUM | TOXICITY | INTESTINES | RADIATION INJURIES | NUCLEAR MEDICINE | ORGANS | DISEASES | DOSES | BODY | HAZARDS
Radiology | Hematology, Oncology and Palliative Medicine | Radiation injury | Rectum | NTCP | MULTICENTER | ONCOLOGY-GROUP | LOCALIZED PROSTATE-CANCER | TISSUE COMPLICATION PROBABILITY | TRIAL | IRRADIATION | LATE TOXICITY | ONCOLOGY | CONFORMAL RADIOTHERAPY | HISTOGRAMS | QUALITY-OF-LIFE | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Radiography | Radiotherapy Dosage | Rectum - diagnostic imaging | Gastrointestinal Hemorrhage - etiology | Models, Biological | Humans | Radiotherapy, Conformal - adverse effects | Risk | Rectum - radiation effects | Models, Statistical | Radiation Injuries - complications | Forecasting | Medical colleges | Analysis | Oncology, Experimental | Radiation | Research | Prostate cancer | Cancer | Index Medicus | GASTROINTESTINAL TRACT | LARGE INTESTINE | BEAMS | DIGESTIVE SYSTEM | RADIATION EFFECTS | PROTON BEAMS | MALE GENITALS | RADIATION DOSES | THREE-DIMENSIONAL CALCULATIONS | MEDICINE | PARTICLE BEAMS | RADIATION DOSE DISTRIBUTIONS | HEALTH HAZARDS | THERAPY | GLANDS | BIOLOGICAL EFFECTS | RADIOLOGY AND NUCLEAR MEDICINE | BIOLOGICAL RADIATION EFFECTS | NUCLEON BEAMS | RADIOTHERAPY | RADIOLOGY | PROSTATE | INJURIES | NEOPLASMS | RECTUM | TOXICITY | INTESTINES | RADIATION INJURIES | NUCLEAR MEDICINE | ORGANS | DISEASES | DOSES | BODY | HAZARDS
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. e498 - e509
Summary Checkpoint blockade immunotherapy has received mainstream attention as a result of striking and durable clinical responses in some patients with...
Hematology, Oncology and Palliative Medicine | MHC CLASS-I | BREAST-CANCER | CALRETICULIN EXPOSURE | DENDRITIC CELLS | ONCOLOGY | ANTITUMOR IMMUNE-RESPONSES | ADVANCED MELANOMA | PROSTATE-CANCER | TUMOR-CELLS | IONIZING-RADIATION | CD8(+) T-CELLS | Cell Death - radiation effects | Immunotherapy - methods | Dendritic Cells - immunology | Humans | Radiation Tolerance | Antibodies, Monoclonal - therapeutic use | Molecular Targeted Therapy | Radiation-Sensitizing Agents - therapeutic use | CD8-Positive T-Lymphocytes - radiation effects | Neoplasms - therapy | Dendritic Cells - drug effects | Cell Death - drug effects | Signal Transduction - radiation effects | Cytotoxicity, Immunologic - drug effects | Chemoradiotherapy - methods | Treatment Outcome | Lymphocytes, Tumor-Infiltrating - drug effects | Radiation Dosage | Dendritic Cells - diagnostic imaging | Radiography | Animals | Signal Transduction - drug effects | Neoplasms - immunology | CD8-Positive T-Lymphocytes - drug effects | CD8-Positive T-Lymphocytes - immunology | Neoplasms - pathology | Cytotoxicity, Immunologic - radiation effects | Lymphocytes, Tumor-Infiltrating - radiation effects | Lymphocytes, Tumor-Infiltrating - immunology | Chemotherapy | Lung cancer | Analysis | Immunotherapy | Melanoma | Radiation | Lymphomas | Cancer
Hematology, Oncology and Palliative Medicine | MHC CLASS-I | BREAST-CANCER | CALRETICULIN EXPOSURE | DENDRITIC CELLS | ONCOLOGY | ANTITUMOR IMMUNE-RESPONSES | ADVANCED MELANOMA | PROSTATE-CANCER | TUMOR-CELLS | IONIZING-RADIATION | CD8(+) T-CELLS | Cell Death - radiation effects | Immunotherapy - methods | Dendritic Cells - immunology | Humans | Radiation Tolerance | Antibodies, Monoclonal - therapeutic use | Molecular Targeted Therapy | Radiation-Sensitizing Agents - therapeutic use | CD8-Positive T-Lymphocytes - radiation effects | Neoplasms - therapy | Dendritic Cells - drug effects | Cell Death - drug effects | Signal Transduction - radiation effects | Cytotoxicity, Immunologic - drug effects | Chemoradiotherapy - methods | Treatment Outcome | Lymphocytes, Tumor-Infiltrating - drug effects | Radiation Dosage | Dendritic Cells - diagnostic imaging | Radiography | Animals | Signal Transduction - drug effects | Neoplasms - immunology | CD8-Positive T-Lymphocytes - drug effects | CD8-Positive T-Lymphocytes - immunology | Neoplasms - pathology | Cytotoxicity, Immunologic - radiation effects | Lymphocytes, Tumor-Infiltrating - radiation effects | Lymphocytes, Tumor-Infiltrating - immunology | Chemotherapy | Lung cancer | Analysis | Immunotherapy | Melanoma | Radiation | Lymphomas | Cancer
Journal Article
Cancer Letters, ISSN 0304-3835, 2013, Volume 356, Issue 1, pp. 82 - 90
Abstract An “abscopal” effect occurs when localized irradiation perturbs the organism as a whole, with consequences that can be either beneficial or...
Hematology, Oncology and Palliative Medicine | Normal tissue effects | Cytokines | Radiotherapy | Abscopal effects | Tumors | Immune system | DNA-DAMAGE | DOUBLE-STRAND BREAKS | TUMOR-CELLS | SPONTANEOUS REGRESSION | CELL LUNG-CANCER | INDUCED BYSTANDER | ONCOLOGY | PROSTATE-CANCER | IN-VIVO | IONIZING-RADIATION | PRIMARY HUMAN FIBROBLASTS | Bystander Effect - radiation effects | Cell Transformation, Neoplastic - radiation effects | Genomic Instability - radiation effects | Apoptosis - radiation effects | Humans | Middle Aged | Male | Inflammation - immunology | Neoplasm Metastasis | Adult | Female | Neoplasms - radiotherapy | Aged | Cytokines - immunology | Radiation | Liver cancer | Hematology | Melanoma | Breast cancer | Lymphomas | Radiation therapy | Metastasis | Patients | Age | Skin cancer
Hematology, Oncology and Palliative Medicine | Normal tissue effects | Cytokines | Radiotherapy | Abscopal effects | Tumors | Immune system | DNA-DAMAGE | DOUBLE-STRAND BREAKS | TUMOR-CELLS | SPONTANEOUS REGRESSION | CELL LUNG-CANCER | INDUCED BYSTANDER | ONCOLOGY | PROSTATE-CANCER | IN-VIVO | IONIZING-RADIATION | PRIMARY HUMAN FIBROBLASTS | Bystander Effect - radiation effects | Cell Transformation, Neoplastic - radiation effects | Genomic Instability - radiation effects | Apoptosis - radiation effects | Humans | Middle Aged | Male | Inflammation - immunology | Neoplasm Metastasis | Adult | Female | Neoplasms - radiotherapy | Aged | Cytokines - immunology | Radiation | Liver cancer | Hematology | Melanoma | Breast cancer | Lymphomas | Radiation therapy | Metastasis | Patients | Age | Skin cancer
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2017, Volume 12, Issue 7, p. e0181951
Ultrasound (US) stimulated microbubbles (MB) is a new treatment approach that sensitizes cancer cells to radiation (XRT). The molecular pathways in this...
SYNTHASE | APOPTOSIS | IN-VITRO | THERAPY | TRIGGERED DRUG | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | FREQUENCY POWER DOPPLER | SPHINGOLIPIDS | ULTRASOUND-STIMULATED MICROBUBBLES | CANCER | Immunohistochemistry | Prostatic Neoplasms - metabolism | Sonication | Ganglioside Galactosyltransferase - genetics | Prostatic Neoplasms - radiotherapy | Apoptosis - radiation effects | Ganglioside Galactosyltransferase - metabolism | Humans | Gene Expression Regulation, Neoplastic | Apoptosis - genetics | Male | Prostatic Neoplasms - genetics | RNA Interference | Microbubbles | Cell Membrane - metabolism | Signal Transduction - radiation effects | Cell Membrane - radiation effects | Ceramides - metabolism | Signal Transduction - genetics | Mice, SCID | Reverse Transcriptase Polymerase Chain Reaction | Cell Survival - radiation effects | Xenograft Model Antitumor Assays | Animals | Cell Line, Tumor | Ultrasonics - methods | Physiological aspects | Cell membranes | Research | Genetically modified organisms | Glycosyltransferases | Radiation | Health sciences | Regulations | Glycosyltransferase | Oncology | Lipids | Acoustics | Metastasis | Assaying | Doppler effect | Oxygen content | Cancer therapies | Signal transduction | Control | Ultrasonic imaging | Reduction | Pathways | Xenografts | Ceramide | Damage | Ultrasound | Drug dosages | Genetic modification | Departments | Cell survival | Saturation | Histology | Breast cancer | Biophysics | Metabolism | Signaling | Cell death | Disruption | Galactose | In vitro methods and tests | Endoplasmic reticulum | Prostate | Tumors | Apoptosis | Cancer
SYNTHASE | APOPTOSIS | IN-VITRO | THERAPY | TRIGGERED DRUG | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | FREQUENCY POWER DOPPLER | SPHINGOLIPIDS | ULTRASOUND-STIMULATED MICROBUBBLES | CANCER | Immunohistochemistry | Prostatic Neoplasms - metabolism | Sonication | Ganglioside Galactosyltransferase - genetics | Prostatic Neoplasms - radiotherapy | Apoptosis - radiation effects | Ganglioside Galactosyltransferase - metabolism | Humans | Gene Expression Regulation, Neoplastic | Apoptosis - genetics | Male | Prostatic Neoplasms - genetics | RNA Interference | Microbubbles | Cell Membrane - metabolism | Signal Transduction - radiation effects | Cell Membrane - radiation effects | Ceramides - metabolism | Signal Transduction - genetics | Mice, SCID | Reverse Transcriptase Polymerase Chain Reaction | Cell Survival - radiation effects | Xenograft Model Antitumor Assays | Animals | Cell Line, Tumor | Ultrasonics - methods | Physiological aspects | Cell membranes | Research | Genetically modified organisms | Glycosyltransferases | Radiation | Health sciences | Regulations | Glycosyltransferase | Oncology | Lipids | Acoustics | Metastasis | Assaying | Doppler effect | Oxygen content | Cancer therapies | Signal transduction | Control | Ultrasonic imaging | Reduction | Pathways | Xenografts | Ceramide | Damage | Ultrasound | Drug dosages | Genetic modification | Departments | Cell survival | Saturation | Histology | Breast cancer | Biophysics | Metabolism | Signaling | Cell death | Disruption | Galactose | In vitro methods and tests | Endoplasmic reticulum | Prostate | Tumors | Apoptosis | Cancer
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2013, Volume 87, Issue 5, pp. 932 - 938
Purpose To give a preliminary report of clinical and treatment factors associated with toxicity in men receiving high-dose radiation therapy (RT) on a phase 3...
Radiology | Hematology, Oncology and Palliative Medicine | ONCOLOGY | RECTAL TOXICITY | VOLUME | ESCALATION TRIAL | RANDOMIZED CONTROLLED-TRIAL | RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Radiotherapy Dosage | Organs at Risk - radiation effects | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Age Factors | Humans | Radiotherapy, Intensity-Modulated - methods | Prostate - radiation effects | Logistic Models | Male | Rectum - radiation effects | Radiation Injuries - complications | Tumor Burden | Urinary Bladder - radiation effects | Quality Assurance, Health Care | Radiotherapy, Intensity-Modulated - adverse effects | Analysis of Variance | Seminal Vesicles - radiation effects | Radiation Injuries - pathology | Radiotherapy, Conformal - adverse effects | Continental Population Groups | Radiotherapy, Conformal - methods | Clinical trials | Sects | Radiotherapy | Nuclear radiation | Prostate cancer | Analysis | Index Medicus | PROSTATE | DISEASE INCIDENCE | NEOPLASMS | RECTUM | RADIOLOGY AND NUCLEAR MEDICINE | RADIATION DOSES | TOXICITY | BLADDER | PLANNING
Radiology | Hematology, Oncology and Palliative Medicine | ONCOLOGY | RECTAL TOXICITY | VOLUME | ESCALATION TRIAL | RANDOMIZED CONTROLLED-TRIAL | RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Radiotherapy Dosage | Organs at Risk - radiation effects | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Age Factors | Humans | Radiotherapy, Intensity-Modulated - methods | Prostate - radiation effects | Logistic Models | Male | Rectum - radiation effects | Radiation Injuries - complications | Tumor Burden | Urinary Bladder - radiation effects | Quality Assurance, Health Care | Radiotherapy, Intensity-Modulated - adverse effects | Analysis of Variance | Seminal Vesicles - radiation effects | Radiation Injuries - pathology | Radiotherapy, Conformal - adverse effects | Continental Population Groups | Radiotherapy, Conformal - methods | Clinical trials | Sects | Radiotherapy | Nuclear radiation | Prostate cancer | Analysis | Index Medicus | PROSTATE | DISEASE INCIDENCE | NEOPLASMS | RECTUM | RADIOLOGY AND NUCLEAR MEDICINE | RADIATION DOSES | TOXICITY | BLADDER | PLANNING
Journal Article
CELL DEATH & DISEASE, ISSN 2041-4889, 10/2013, Volume 4, Issue 10, pp. e875 - e875
Radioresistance is a major challenge in prostate cancer (CaP) radiotherapy (RT). In this study, we investigated the role and association of...
BEZ235 | RADIATION SENSITIVITY | IDENTIFICATION | EMT | PI3K/Akt/mTOR | CELL BIOLOGY | CSC | IN-VITRO | radiation therapy | PROTEASOME | RESISTANCE | INHIBITOR | Prostate cancer | radioresistance | Prostatic Neoplasms - radiotherapy | Epithelial-Mesenchymal Transition - radiation effects | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Apoptosis - radiation effects | Neoplastic Stem Cells - drug effects | Humans | Spheroids, Cellular - pathology | Epithelial-Mesenchymal Transition - drug effects | Male | Phosphatidylinositol 3-Kinases - metabolism | Spheroids, Cellular - radiation effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Quinolines - pharmacology | Radiation Tolerance - radiation effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | Neoplastic Stem Cells - pathology | Spheroids, Cellular - drug effects | Imidazoles - therapeutic use | Signal Transduction - radiation effects | Proto-Oncogene Proteins c-akt - metabolism | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Reproducibility of Results | Neoplasm Invasiveness | Imidazoles - pharmacology | Enzyme Activation - drug effects | Enzyme Activation - radiation effects | Radiation Tolerance - drug effects | Phenotype | Animals | Cell Cycle Checkpoints - radiation effects | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | Models, Biological | Cell Line, Tumor | Prostatic Neoplasms - enzymology | Quinolines - therapeutic use | Neoplastic Stem Cells - enzymology | PI3K | mTOR | Akt | Original
BEZ235 | RADIATION SENSITIVITY | IDENTIFICATION | EMT | PI3K/Akt/mTOR | CELL BIOLOGY | CSC | IN-VITRO | radiation therapy | PROTEASOME | RESISTANCE | INHIBITOR | Prostate cancer | radioresistance | Prostatic Neoplasms - radiotherapy | Epithelial-Mesenchymal Transition - radiation effects | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Apoptosis - radiation effects | Neoplastic Stem Cells - drug effects | Humans | Spheroids, Cellular - pathology | Epithelial-Mesenchymal Transition - drug effects | Male | Phosphatidylinositol 3-Kinases - metabolism | Spheroids, Cellular - radiation effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Quinolines - pharmacology | Radiation Tolerance - radiation effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | Neoplastic Stem Cells - pathology | Spheroids, Cellular - drug effects | Imidazoles - therapeutic use | Signal Transduction - radiation effects | Proto-Oncogene Proteins c-akt - metabolism | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Reproducibility of Results | Neoplasm Invasiveness | Imidazoles - pharmacology | Enzyme Activation - drug effects | Enzyme Activation - radiation effects | Radiation Tolerance - drug effects | Phenotype | Animals | Cell Cycle Checkpoints - radiation effects | Signal Transduction - drug effects | Cell Cycle Checkpoints - drug effects | Models, Biological | Cell Line, Tumor | Prostatic Neoplasms - enzymology | Quinolines - therapeutic use | Neoplastic Stem Cells - enzymology | PI3K | mTOR | Akt | Original
Journal Article
American Family Physician, ISSN 0002-838X, 2010, Volume 82, Issue 4, pp. 381 - 388
Nearly two thirds of patients with cancer will undergo radiation therapy as part of their treatment plan. Given the increased use of radiation therapy and the...
Internal Medicine | HEMORRHAGIC CYSTITIS | MEDICINE, GENERAL & INTERNAL | PRACTICE GUIDELINE | INDUCED EMESIS | PROSTATE-CANCER | DOUBLE-BLIND | CARDIOVASCULAR-DISEASE | RANDOMIZED-TRIAL | PRIMARY HEALTH CARE | ERECTILE DYSFUNCTION | AMERICAN-SOCIETY | SKIN REACTIONS | Fatigue - drug therapy | Humans | Risk Factors | Sexual Dysfunction, Physiological - drug therapy | Fatigue - etiology | Gastrointestinal Tract - radiation effects | Male | Dermatologic Agents - therapeutic use | Radiotherapy - adverse effects | Vomiting - drug therapy | Depression - etiology | Depression - drug therapy | Dermatitis - etiology | Neoplasms - complications | Cardiovascular System - radiation effects | Sexual Dysfunction, Physiological - etiology | Antiemetics - therapeutic use | Vomiting - etiology | Female | Lung - radiation effects | Neoplasms - radiotherapy | Dermatitis - drug therapy | Complications and side effects | Usage | Care and treatment | Depression, Mental | Skin | Inflammation | Diagnosis | Radiotherapy | Dermatitis | Risk factors | Cancer
Internal Medicine | HEMORRHAGIC CYSTITIS | MEDICINE, GENERAL & INTERNAL | PRACTICE GUIDELINE | INDUCED EMESIS | PROSTATE-CANCER | DOUBLE-BLIND | CARDIOVASCULAR-DISEASE | RANDOMIZED-TRIAL | PRIMARY HEALTH CARE | ERECTILE DYSFUNCTION | AMERICAN-SOCIETY | SKIN REACTIONS | Fatigue - drug therapy | Humans | Risk Factors | Sexual Dysfunction, Physiological - drug therapy | Fatigue - etiology | Gastrointestinal Tract - radiation effects | Male | Dermatologic Agents - therapeutic use | Radiotherapy - adverse effects | Vomiting - drug therapy | Depression - etiology | Depression - drug therapy | Dermatitis - etiology | Neoplasms - complications | Cardiovascular System - radiation effects | Sexual Dysfunction, Physiological - etiology | Antiemetics - therapeutic use | Vomiting - etiology | Female | Lung - radiation effects | Neoplasms - radiotherapy | Dermatitis - drug therapy | Complications and side effects | Usage | Care and treatment | Depression, Mental | Skin | Inflammation | Diagnosis | Radiotherapy | Dermatitis | Risk factors | Cancer
Journal Article
Lancet Oncology, ISSN 1470-2045, 2003, Volume 4, Issue 9, pp. 529 - 536
The use of radiation therapy to treat cancer inevitably involves exposure of normal tissues. As a result, patients may experience symptoms associated with...
APOPTOSIS | INDUCED PULMONARY FIBROSIS | THERAPY | ONCOLOGY | CONFORMAL RADIOTHERAPY | PROSTATE-CANCER | GASTROINTESTINAL-TRACT | INDUCED LUNG INJURY | CONVERTING ENZYME-INHIBITORS | DAMAGE | GROWTH-FACTOR BETA-1 | Animals | Radiation Injuries - prevention & control | Humans | Radiation-Protective Agents - therapeutic use | Neoplasms - radiotherapy | Radiation Injuries - pathology | Radiotherapy - adverse effects | Radiation Injuries - etiology | Radiation | Radiogenetics
APOPTOSIS | INDUCED PULMONARY FIBROSIS | THERAPY | ONCOLOGY | CONFORMAL RADIOTHERAPY | PROSTATE-CANCER | GASTROINTESTINAL-TRACT | INDUCED LUNG INJURY | CONVERTING ENZYME-INHIBITORS | DAMAGE | GROWTH-FACTOR BETA-1 | Animals | Radiation Injuries - prevention & control | Humans | Radiation-Protective Agents - therapeutic use | Neoplasms - radiotherapy | Radiation Injuries - pathology | Radiotherapy - adverse effects | Radiation Injuries - etiology | Radiation | Radiogenetics
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2010, Volume 76, Issue 3, pp. S116 - S122
An in-depth overview of the normal-tissue radiation tolerance of the urinary bladder is presented. The most informative studies consider whole-organ...
Radiology | Hematology, Oncology and Palliative Medicine | toxicity | Bladder dose | LATE COMPLICATIONS | RADICAL HYSTERECTOMY | LOCALIZED PROSTATE-CANCER | ICRU REFERENCE | RANDOMIZED-TRIAL | CERVICAL-CANCER | UTERINE CERVIX | ONCOLOGY | CONCOMITANT BOOST | TRANSITIONAL CELL-CARCINOMA | 3-DIMENSIONAL CONFORMAL RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Radiotherapy Dosage | Prostatic Neoplasms - radiotherapy | Movement | Uterine Cervical Neoplasms - radiotherapy | Humans | Radiation Tolerance | Male | Prostatectomy - adverse effects | Radiation Injuries - complications | Forecasting | Urinary Bladder - radiation effects | Radiography | Urinary Bladder Neoplasms - radiotherapy | Models, Biological | Urinary Bladder - diagnostic imaging | Female | Hysterectomy - adverse effects | Analysis | Radiation | INJURIES | RADIATION EFFECTS | RADIATION DOSES | TOXICITY | RADIATION INJURIES | IRRADIATION | ORGANS | URINARY TRACT | DISEASES | BIOLOGICAL EFFECTS | DOSES | RADIOLOGY AND NUCLEAR MEDICINE | BIOLOGICAL RADIATION EFFECTS | BLADDER | NONUNIFORM IRRADIATION | BODY
Radiology | Hematology, Oncology and Palliative Medicine | toxicity | Bladder dose | LATE COMPLICATIONS | RADICAL HYSTERECTOMY | LOCALIZED PROSTATE-CANCER | ICRU REFERENCE | RANDOMIZED-TRIAL | CERVICAL-CANCER | UTERINE CERVIX | ONCOLOGY | CONCOMITANT BOOST | TRANSITIONAL CELL-CARCINOMA | 3-DIMENSIONAL CONFORMAL RADIOTHERAPY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Radiotherapy Dosage | Prostatic Neoplasms - radiotherapy | Movement | Uterine Cervical Neoplasms - radiotherapy | Humans | Radiation Tolerance | Male | Prostatectomy - adverse effects | Radiation Injuries - complications | Forecasting | Urinary Bladder - radiation effects | Radiography | Urinary Bladder Neoplasms - radiotherapy | Models, Biological | Urinary Bladder - diagnostic imaging | Female | Hysterectomy - adverse effects | Analysis | Radiation | INJURIES | RADIATION EFFECTS | RADIATION DOSES | TOXICITY | RADIATION INJURIES | IRRADIATION | ORGANS | URINARY TRACT | DISEASES | BIOLOGICAL EFFECTS | DOSES | RADIOLOGY AND NUCLEAR MEDICINE | BIOLOGICAL RADIATION EFFECTS | BLADDER | NONUNIFORM IRRADIATION | BODY
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2017, Volume 23, Issue 6, pp. 1388 - 1396
Purpose: Little prospective data are available on clinical outcomes and immune correlates from combination radiation and immunotherapy. We conducted a phase I...
TRIAL | CTLA-4 BLOCKADE | LUNG-CANCER | MELANOMA | SOLID TUMORS | ONCOLOGY | IMMUNOTHERAPY | EARLY-STAGE | RADIOTHERAPY | RESISTANT PROSTATE-CANCER | COMBINATION | Lung Neoplasms - drug therapy | Liver - pathology | Humans | Middle Aged | CD4-Positive T-Lymphocytes - radiation effects | Lung Neoplasms - radiotherapy | Liver - radiation effects | Lung Neoplasms - pathology | Male | Radiosurgery - adverse effects | CD8-Positive T-Lymphocytes - radiation effects | Flow Cytometry | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Lung - radiation effects | Ipilimumab - administration & dosage | Lung - pathology | Liver Neoplasms - drug therapy | Treatment Outcome | Combined Modality Therapy | Ipilimumab - adverse effects | CD8-Positive T-Lymphocytes - drug effects | Liver Neoplasms - radiotherapy | Lung - drug effects | Aged | Biomarkers, Tumor - genetics | CD4-Positive T-Lymphocytes - drug effects | Flow cytometry | Toxicity | CD8 antigen | Liver | Radiation | Activation | Lymphocytes T | T cell receptors | Radiation therapy | Patients | CD4 antigen | Liver cancer | Cytometry | Cell activation | Lungs | Experimental design | Lymphocytes | Immunotherapy | ICOS protein | Irradiation | Cancer | Index Medicus | trial correlates | Stereotactic ablative radiation therapy | immunotherapy | ipilimumab
TRIAL | CTLA-4 BLOCKADE | LUNG-CANCER | MELANOMA | SOLID TUMORS | ONCOLOGY | IMMUNOTHERAPY | EARLY-STAGE | RADIOTHERAPY | RESISTANT PROSTATE-CANCER | COMBINATION | Lung Neoplasms - drug therapy | Liver - pathology | Humans | Middle Aged | CD4-Positive T-Lymphocytes - radiation effects | Lung Neoplasms - radiotherapy | Liver - radiation effects | Lung Neoplasms - pathology | Male | Radiosurgery - adverse effects | CD8-Positive T-Lymphocytes - radiation effects | Flow Cytometry | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Lung - radiation effects | Ipilimumab - administration & dosage | Lung - pathology | Liver Neoplasms - drug therapy | Treatment Outcome | Combined Modality Therapy | Ipilimumab - adverse effects | CD8-Positive T-Lymphocytes - drug effects | Liver Neoplasms - radiotherapy | Lung - drug effects | Aged | Biomarkers, Tumor - genetics | CD4-Positive T-Lymphocytes - drug effects | Flow cytometry | Toxicity | CD8 antigen | Liver | Radiation | Activation | Lymphocytes T | T cell receptors | Radiation therapy | Patients | CD4 antigen | Liver cancer | Cytometry | Cell activation | Lungs | Experimental design | Lymphocytes | Immunotherapy | ICOS protein | Irradiation | Cancer | Index Medicus | trial correlates | Stereotactic ablative radiation therapy | immunotherapy | ipilimumab
Journal Article
Cell Death and Disease, ISSN 2041-4889, 01/2014, Volume 5, Issue 10, pp. e1437 - e1437
The PI3K/Akt/mTOR pathway has a central role in cancer metastasis and radiotherapy. To develop effective therapeutics to improve radiosensitivity,...
TRANSITION | ACTIVATION | DUAL PI3K/MTOR INHIBITOR | DOUBLE-STRAND BREAKS | CYCLIN-DEPENDENT KINASE | TOXICITY | LINES | RADIATION-THERAPY | P53 | CELL BIOLOGY | Prostatic Neoplasms - radiotherapy | Homologous Recombination - drug effects | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Apoptosis - radiation effects | DNA End-Joining Repair - radiation effects | Humans | Male | Phosphatidylinositol 3-Kinases - metabolism | Prostatic Neoplasms - physiopathology | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Autophagy | Proto-Oncogene Proteins c-akt - genetics | Radiation Tolerance - radiation effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | Prostatic Neoplasms - genetics | TOR Serine-Threonine Kinases - genetics | Signal Transduction - radiation effects | Proto-Oncogene Proteins c-akt - metabolism | Prostatic Neoplasms - drug therapy | DNA End-Joining Repair - drug effects | Homologous Recombination - radiation effects | Cell Cycle - radiation effects | Enzyme Inhibitors - pharmacology | Phosphatidylinositol 3-Kinases - genetics | Radiation Tolerance - drug effects | Signal Transduction - drug effects | Cell Line, Tumor | Cell Cycle - drug effects | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Original
TRANSITION | ACTIVATION | DUAL PI3K/MTOR INHIBITOR | DOUBLE-STRAND BREAKS | CYCLIN-DEPENDENT KINASE | TOXICITY | LINES | RADIATION-THERAPY | P53 | CELL BIOLOGY | Prostatic Neoplasms - radiotherapy | Homologous Recombination - drug effects | TOR Serine-Threonine Kinases - metabolism | Apoptosis - drug effects | Apoptosis - radiation effects | DNA End-Joining Repair - radiation effects | Humans | Male | Phosphatidylinositol 3-Kinases - metabolism | Prostatic Neoplasms - physiopathology | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Autophagy | Proto-Oncogene Proteins c-akt - genetics | Radiation Tolerance - radiation effects | TOR Serine-Threonine Kinases - antagonists & inhibitors | Prostatic Neoplasms - genetics | TOR Serine-Threonine Kinases - genetics | Signal Transduction - radiation effects | Proto-Oncogene Proteins c-akt - metabolism | Prostatic Neoplasms - drug therapy | DNA End-Joining Repair - drug effects | Homologous Recombination - radiation effects | Cell Cycle - radiation effects | Enzyme Inhibitors - pharmacology | Phosphatidylinositol 3-Kinases - genetics | Radiation Tolerance - drug effects | Signal Transduction - drug effects | Cell Line, Tumor | Cell Cycle - drug effects | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Original
Journal Article